

Curriculum Vitae

Herbert (He) YU

Business Address: Section of Cancer Prevention and Control
Feist-Weiller Cancer Center
Department of Medicine
Louisiana State University Health Sciences Center
1501 Kings Highway
Shreveport, LA
77130-3932
U.S.A.

Phone: 318-675-4552
Fax: 318-675-7600
Email: hyu@lsuonc.edu

Education:

1992-1996 *Ph.D. (Clinical Biochemistry)*, University of Toronto, Toronto, Canada
1988-1990 *M.Sc. (Epidemiology)*, University of Toronto, Toronto, Canada
1978-1983 *MD*, Shanghai Medical University, Shanghai, P.R. China

Professional Experience:

1998-present: *Assistant Professor*, Department of Medicine, Section of Cancer Prevention and Control, Louisiana State University Medical Center, Shreveport, LA.
1996-1998: *Senior Scientist*, Diagnostic Systems Laboratories, Houston, TX.
1993-1996: *Research Associate*, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; and Department of Clinical Biochemistry, University of Toronto, Toronto, Canada.
1989-1992: *Research Assistant*, Epidemiology Unit, National Cancer Institute of Canada and Department of Preventive Medicine and Biostatistics, University of Toronto, Toronto, Canada.
1986-1988: *Visiting Fellow*, Division of Epidemiology, American Health Foundation, New York City, USA.
1983-1986: *Junior Epidemiologist*, Division of Epidemiology, Shanghai Cancer Institute, Shanghai, P.R. China.

Awards and Honours:

1998 Young Investigator Award, Louisiana State University Medical Center in Shreveport
1995 Best Abstract Award, 21st National and 1st International Meeting, Clinical Ligand Assay Society
1994 Best Poster Presentation Award, 1994 Annual Meeting, Canadian Society of Clinical Chemistry
1994 AACC Student Travel Award for the 1994 Annual Meeting, American Association for Clinical Chemistry
1994 Best Student Poster Presentation Award, 1994 AACC Annual Meeting, American Association for Clinical Chemistry
1993 Mitchell Scholarship in Cancer Research, Life Science Committee, University of Toronto

- 1993** Young Investigator Award, AACC Upstate New York Section,
American Association for Clinical Chemistry
- 1988** Fellowship for Epidemiology Study, Epidemiology Unit, National Cancer Institute of Canada
- 1986** Wang Fellowship for International Study of Public Health, American Health Foundation

Society Membership:

- 1994-1996 American Association for Clinical Chemistry
- 1998- Society for Epidemiologic Research
- 1998- American College of Epidemiology
- 1999- American Association for Cancer Research
- 1999- American Association for Preventive Oncology
- 1999- American Association for the Advancement of Science
- 1999- The Endocrine Society

Research Grants:

Louisiana State University Medical Center
Young Investigator Award 07/01/98 – 06/30/99 \$10,000
Title: Insulin-like growth factors in prognosis of prostate cancer
PI: **Yu H**

NIH (R03CA80704)
NCI – Cancer Epidemiology 09/30/98 – 09/29/00 \$107,417
Title: Diet- and lifestyle-related insulin-like growth factor-I expression and breast cancer risk
PI: **Yu H**

DOD (BC984008)
Clinical Translational Research 07/01/99-06/30/04 \$359,782
Title: High eIF4E overexpression in node negative breast cancer as predictor for recurrence
PI: Li BDL
Co-investigator: **Yu H**

NIH (R03CA83050)
NCI – Cancer Epidemiology 06/30/99 – 06/29/01 \$143,695
Title: Interaction between estrogens and insulin-like growth factors in breast cancer
PI: **Yu H**

Publications:

- Yu H**, Tu JT. Mortality experience of primary liver cancer in Chongming county, Shanghai, 1974-1983. Shanghai Cancer Institute Report 1984. (in Chinese)
- Tu JT, **Yu H**. The risk factors of primary liver cancer, a five-year prospective study. Shanghai Cancer Institute Report 1985. (in Chinese)
- Yu H**, Yang KY, Tu JT. A case-control study of drinking water and gastric cancer in a geologic fault area. Tumour 4:107-110, 1986. (in Chinese)

4. **Yu H**, Harris RE, Kabat GC, Wynder EL. Cigarette smoking, alcohol consumption and primary liver cancer: a case-control study in the USA. **Int J Cancer** 42:325-328, 1988.
5. **Yu H**, Harris RE, Wynder EL. Case-control study of prostate cancer and socio-economic factors. **The Prostate** 13:317-325, 1988.
6. Rohan TE, Mann V, Mclaughlin J, Harnish DG, **Yu H**, and et al. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. **Int J Cancer** 49:856-860, 1991.
7. **Yu H**, Harris RE, Gao YT, Gao R, Wynder EL. Comparative epidemiology of cancers of colon, rectum, prostate and breast in China versus the United States. **Int J Epidemiol** 20:76-81, 1991.
8. **Yu H**, Rohan TE, Cook MG, Howe GR, Miller AB. Risk factors for fibroadenoma: a case-control study in Australia. **Am J Epidemiol** 135:247-58, 1992.
9. **Yu H**, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate specific antigen in serum and preliminary clinical studies. **Clin Chem** 39:2108-2114, 1993.
10. **Yu H**, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. **Clin Biochem** 27:75-79, 1994.
11. **Yu H**, Diamandis EP, Levesque MA, and et al. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. **J Clin Lab Analysis** 8:251-253, 1994.
12. Diamandis EP, **Yu H**, Sutherland DJA. Detection of prostate specific antigen immunoreactivity in breast tumors. **Breast Cancer Res Treat** 32:291-300, 1994.
13. **Yu H**, Diamandis EP, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in the breast cancer cell lines. **Breast Cancer Res Treat** 32:301-310, 1994.
14. Levesque MA, Diamandis EP, **Yu H**, Sutherland DJA. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. **Breast Cancer Res Treat** 30:179-195, 1994.
15. Monne M, Croce CM, **Yu H**, Diamandis EP. Molecular characterization of prostate specific antigen mRNA expressed in breast tumors. **Cancer Res** 41:6344-6347, 1994.
16. Levesque MA, Katsaros D, **Yu H**, Diamandis EP, and et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. **Cancer** 75:1327-1338, 1995.
17. **Yu H**, Diamandis EP. Measurement of prostate specific antigen level in the serum of females and prostatectomized males with an ultrasensitive immunoassay technique. **J Urol** 153:1004-1008, 1995.
18. **Yu H**, Giai M, Diamandis EP, Sutherland DJA, and et al. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. **Cancer Res** 55:2104-2110, 1995.
19. **Yu H**, Diamandis EP. Prostate specific antigen immunoreactivity in amniotic fluid. **Clin Chem** 41:204-210, 1995.
20. **Yu H**, Diamandis EP, Monne M, Croce CM. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. **J Biol Chem** 270:6615-6618, 1995.
21. **Yu H**, Diamandis EP. Protease prostate specific antigen in milk of lactating women. **Clin Chem** 41:54-60, 1995.

22. **Yu H**, Diamandis EP, Prestigiacomo AF, Stamey TA. Early detection of prostate cancer relapse and estimation of tumor doubling time post-radical prostatectomy with an ultrasensitive prostate specific antigen assay. **Clin Chem** 41:430-434, 1995.
23. Levesque MA, **Yu H**, D'Costa M, Diamandis EP. Prostate specific antigen expression by various tumors. **J Clin Lab Analysis** 9:123-128, 1995.
24. **Yu H**, Diamandis EP, Levesque M, Asa SL, Monne M, Croce CM. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. **Cancer Res** 55:1603-1606, 1995.
25. Gai M, **Yu H**, Katsaros D, Diamandis EP. Comparison of prostate specific antigen in the serum of normal women and women with breast cancer before or after surgery. **Br J Cancer** 72:728-731, 1995.
26. Zarghami N, **Yu H**, Diamandis EP, Sutherland DJA. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. **Clin Biochem** 28:243-253, 1995.
27. Levesque MA, Clark GM, **Yu H**, Diamandis EP. Immunofluorometric analysis of p53 protein and prostate specific antigen in breast tumors and their association with other prognostic indicators. **Br J Cancer** 72:720-727, 1995.
28. Levesque MA, **Yu H**, D'Costa M, Tadross L, Diamandis EP. Immunoreactive prostate specific antigen in lung tumors. **J Clin Lab Analysis** 9:375-379, 1995.
29. Zarghami N, Katsaros D, **Yu H**, and Diamandis EP. Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma. **Canadian J Oncol** 5:401-407, 1995.
30. Diamandis EP, **Yu H**. Prostate cancer, prostate specific antigen, and the polymerase chain reaction. **Clin Chem** 41:177-179, 1995. (Editorials)
31. Diamandis EP, **Yu H**: New biological functions of prostate specific antigen. **J Clin Endocrinol & Metab** 80:1515-1517, 1995. (Editorials)
32. Diamandis EP, **Yu H**. Prostate specific antigen and lack of specificity for prostate cells. **Lancet** 345:1186, 1995. (Letters to the Editor)
33. Diamandis EP, **Yu H**, Lopez-Otin C. Prostate specific antigen - a new constituent of breast cyst fluid. **Breast Cancer Res Treat** 38:259-264, 1996.
34. Zarghami N, Gai M, **Yu H**, Katsaros D, Diamandis EP. Creatine kinase BB isoenzyme levels in tumor cytosols and survival of breast cancer patients. **Br J Cancer** 73:386-390, 1996.
35. Hoffman BR, **Yu H**, Diamandis EP. Assay of prostate specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. **Clin Chem** 42:536-544, 1996.
36. Ferguson RA, **Yu H**, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive Detection of prostate specific antigen by a new time resolved immunofluorometric assay and the Immulite immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. **Clin Chem** 42:675-684, 1996.
37. Melegos DN, **Yu H**, Diamandis EP. Prostaglandin D2 synthase - a new component of human amniotic fluid and its association with fetal abnormalities. **Clin Chem** 42:1042-1050, 1996.
38. **Yu H**, Diamandis EP, Levesque M, Gai M, Roagna R, Ponzzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. **Breast Cancer Res Treat** 40:171-178, 1996.

39. **Yu H**, Levesque MA, Mohammad JK, Papanastasiou-Diamandis A, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. **Br J Cancer** 74:1242-1247, 1996.
40. Angelopoulou K, Rosen B, Straitis M, **Yu H**, Solomou M, Diamandis EP. Circulating antibodies against p53 protein in patients with ovarian cancer: correlation with clinicopathological features and survival. **Cancer** 77:2146-2152, 1996.
41. Melegos DN, **Yu H**, Allen LC, and Diamandis EP. Prostate specific antigen in amniotic fluid of normal and abnormal pregnancies. **Clin Biochem** 29:555-562, 1996.
42. Diamandis EP, **Yu H**. Clinical usefulness of prostate specific antigen. **J Urol** 154:294, 1996. (Letters to the Editor)
43. Diamandis EP, **Yu H**, Melegos DN. Ultrasensitive prostate specific antigen assays and their clinical application. **Clin Chem** 42:853-857, 1996. (Editorials)
44. Diamandis EP, **Yu H**. Dose prostate cancer start at puberty? **J Clin Lab Anal** 10:468-469, 1996.
45. **Yu H**, Diamandis EP, Wong P-Y, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels between 0.001-0.1 ug/L. **J Urol** 157:913-918, 1997.
46. Melegos DN, **Yu H**, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate specific antigen in female serum - a potential new marker of androgen excess. **J Clin Endocrinol & Meta** 82:777-780, 1997.
47. Sauter ER, Daly M, Lenahan K, Ehya H, Engstrom PF, Sorling A, Bonney G, **Yu H**, Diamandis EP. Prostate specific antigen in nipple aspirate fluid correlate with breast cancer risk. **Cancer Epidemiol Biomarkers Prevent** 5:967-970, 1997.
48. Diamandis EP, **Yu H**. Non-prostate sources of prostate specific antigen. In: "**Urologic Clinics of North America on Prostate Specific Antigen: the best prostatic tumor marker**". 24:275-282, 1997 (Book chapter)
49. **Yu H**, Levesque M, Clark G, Diamandis EP. Prognostic value of prostate specific antigen for women with breast cancer - a large U.S. cohort study. **Clin Cancer Res** 4:1489-1497, 1998.
50. Levesque MA, **Yu H**, Clark GM, Diamandis EP. ELISA-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. **J Clin Oncol** 16:2641-2650, 1998.
51. Levesque MA, Katsaros D, **Yu H**, Giai M, Roagna R, Ponzzone R, Sismondi P, Diamandis EP. Immunofluorometrically-determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. **Int J Cancer** 79:147-152, 1998.
52. Juul A, Moller S, Mosfeldt-Laursen E, Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, **Yu H**, et al. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. **J Clin Endocrinol & Metab** 83:4408-4415, 1998.
53. **Yu H**, Levesque MA, Khosravi MJ, Clark GM, Diamandis EP. Insulin-like growth factor binding protein-3 and breast cancer survival. **Int J Cancer** 79:624-628, 1998.
54. **Yu H**. Alcohol consumption and breast cancer risk. **JAMA** 280:1138-1139, 1998. (Letters to the Editor)

55. **Yu H**, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. High plasma levels of insulin-like growth factor-I (IGF-I) in association with lung cancer risk, a case-control study. **J Natl Cancer Inst** 91:151-156, 1999.
56. Foekins JA, EP Diamandis, **Yu H**, Look MP, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM. Expression of prostate specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. **Br J Cancer** 79:888-894, 1999.
57. Lianidou ES, Levesque MA, Angelopoulou K, **Yu H**, Katsaros D, Diamandis EP. Mutational analysis versus ELISA for the detection of p53 gene abnormalities in ovarian carcinoma: implications for response to chemotherapy. **Anticancer Research** 19:799-806, 1999.
58. Diamandis EP, Helle SI, **Yu H**, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast cancer. **Cancer** 85:891-898, 1999.
59. Borchert GH, **Yu H**, Tomlinson G, Giai M, Roagna R, Ponzzone R, Sgro L, Diamandis EP. Prostate specific antigen molecular forms in breast cyst fluid and serum of women with benign breast disease. **J Clin Lab Analysis** 13:75-81, 1999.
60. **Yu H**. Association between insulin-like growth factor-I (IGF-I) and bone mineral density, further evidence linking IGF-I to breast cancer risk. **J Clin Endocrinol & Metab** 84:1760, 1999. (Letters to the Editor)
61. **Yu H**, Berkel H. Prostate specific antigen (PSA) in women. **J La State Med Soc** 151:218-223, 1999.
62. **Yu H**, Berkel H. Insulin-like growth factors and cancer. **J La State Med Soc** 151:209-213; 1999.
63. Diamandis EP, Arnett WP, Foussias G, Pappas H, Ghandi S, Melegos DN, Mullen B, **Yu H**, Srigley J, Jarvi K. Seminal plasma biochemical markers and their association with semen analysis findings. **Urology** 53:596-603; 1999.
64. **Yu H**, Berkel H. Do insulin-like growth factors mediate the effect of alcohol on breast cancer risk? **Medical Hypotheses** 52:491-496; 1999.
65. **Yu H**, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J, Juul A. Insulin-like growth factors (IGF-I, free IGF-I, IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6 and ALS) in blood circulation. **J Clin Lab Anal** 13:166-172; 1999.
66. Borchert GH, Melegos DN, **Yu H**, Giai M, Roagna R, Ponzzone R, Sgro L, Diamandis EP. Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. **Clin Biochem** 32:39-44; 1999.
67. **Yu H**, Levesque M, Clark G, Diamandis EP. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and PSA in combination. **Br J Cancer** 81:490-495; 1999.
68. **Yu H**. Re: Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. **J Natl Cancer Inst** 91:1685; 1999. (Letters to the Editor)
69. **Yu H**, Diamandis EP, Hoffman B. The role of androgen and androgen receptor in breast cancer. **Ann Intern Med** 131:715; 1999. (Letters to the Editor)
70. Black M, Giai M, Ponzzone R, Sismondi P, **Yu H**, Diamandis EP. Serum total and free PSA for breast cancer diagnosis in women. **Clin Cancer Res** (in press) 1999.
71. **Yu H**. Clinical implications of prostate specific antigen in men and women. **J Gender-Specific Med** (in press) 1999.

72. Angelopoulou K, **Yu H**, Bharaj B, Giai M, Diamandis EP. P53 gene mutation, tumor p53 protein overexpression and autoantibody generation in patients with breast cancer. **Clin Biochem** (in press) 1999.
73. Wu X, **Yu H**, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. **J Natl Cancer Inst** (in press) 1999.
74. **Yu H**, Bharaj BS, Vassilikos EJK, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. **Breast Cancer Res Treat** (in press) 2000.

Abstracts:

1. Diamandis EP, **Yu H**, Grass L. Androgens, progestins and tamoxifen induce PSA production in the breast cancer cell line T-47D. *Clin Biochem*, 27:232; 1994.
2. **Yu H**, Diamandis EP, Sutherland DJA. Detection of prostate specific antigen in breast tumors. *Clin Biochem*, 27:232; 1994.
3. Levesque M, Diamandis EP, **Yu H**, Sutherland DJA. Quantitative analysis of prostate specific antigen and mutant p53 protein in breast tumor cytosols: Relationship with other prognostic indicators. *Clin Biochem*, 27:232; 1994.
4. **Yu H**, Diamandis EP, Giai M, Ponzzone R, Sismondi P, Katsaros D. Evaluation of prostate specific antigen as a prognostic and predictive indicator for breast cancer patients. *Eur J Cancer*, 30A:548; 1994.
5. **Yu H**, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen in breast cancer cytosols and its association with steroid hormone receptors. *AACR Proceeding* 36:245; 1995.
6. **Yu H**, Diamandis EP. Prostate specific antigen (PSA) as a new prognostic marker in female breast cancer: molecular characterization and clinical implication. *AACR Proceedings* 36:246; 1995.
7. Monne M, Croce CM, **Yu H**, Diamandis EP. Molecular characterization of prostate specific antigen mRNA expressed in breast tumors. *AACR Proceedings* 36:346; 1995.
8. Melegos DN, **Yu H**, Allen LC, Diamandis EP. Prostate specific antigen in amniotic fluid and maternal serum. *J Clin Ligand Assay* 18:66; 1995.
9. Melegos DN, **Yu H**, Allen LC, Diamandis EP. Prostate specific antigen in amniotic fluid and maternal serum. Possible associations with fetal abnormalities. *Clin Chem* 41:26; 1995.
10. **Yu H**, Diamandis EP. Identification of prostate specific antigen in milk of lactating women. *Clin Chem* 41:27; 1995.
11. Zarghami N, Giai M, **Yu H**, Katsaros D, Diamandis EP. Creatine kinase BB isoenzyme levels in tumor cytosols and survival of breast cancer patients. *Clin Chem* 41:815; 1995.
12. **Yu H**, Diamandis EP, Levesque MA, Asa S, Monne M, Croce CM. Expression of the prostate specific antigen gene in a primary ovarian carcinoma. *Clin Chem* 41:816; 1995.
13. Levesque MA, Diamandis EP, **Yu H**, Zola P, Sismondi P, Giardina G, Katsaros D. Immunofluorometrically quantified p53 protein as a prognostic indicator in ovarian carcinoma. *Clin Chem* 41:839; 1995.

14. Randell EW, **Yu H**, Diamandis EP, Ellis G. Prostate specific antigen in neonates and infants. *Clin Chem* 41:866; 1995.
15. Levesque MA, Diamandis EP, **Yu H**, Zola P, Sismondi P, Giardina G, Katsaros D. Prognostic value of immunofluorometrically quantified p53 protein in ovarian carcinoma. *Clin Biochem* 28:340; 1995.
16. Zarghami N, Giai M, **Yu H**, Katsaros D, Diamandis EP. Association between breast cancer patient survival and levels of creatine kinase BB in tumor cytosols. *Clin Biochem* 28:341; 1995.
17. **Yu H**, Diamandis EP, Levesque MA, Asa S, Monne M, Croce CM. Prostate specific antigen gene expression in ovarian cancer post-liver transplantation. *Clin Biochem* 28:341; 1995.
18. **Yu H**, Diamandis EP. The milk of lactating women contains prostate specific antigen. *Clin Biochem* 28:341; 1995.
19. Melegos DN, **Yu H**, Allen LC, Diamandis EP. A possible association between fetal abnormalities and levels of prostate specific antigen in amniotic fluid. *Clin Biochem* 28:341; 1995.
20. Hoffman BR, **Yu H**, Diamandis EP. Prostate specific screening using prostate specific antigen extracted from dried blood on filter paper. *Clin Biochem* 28:342; 1995.
21. **Yu H**, Diamandis EP, Sutherland DJA, Giai M, Katsaros D, Monne M, Croce CM. Prostate specific antigen in breast cancer and its potential for clinical application. *J Tumor Marker Oncology* 10:50; 1995.
22. **Yu H**, Levesque MA, Khosravi MJ, Papanastasiou-Diamandis A, Clark GM, Diamandis EP. No associations between IGFBP-3 and p53, or PSA in breast cancer. *AACR Proceedings* 37:189; 1996
23. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Sorling A, Bonney G, Ross E, **Yu H**, Diamandis EP. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. *AACR Proceedings* 37:213; 1996.
24. **Yu H**, Levesque MA, Khosravi MJ, Papanastasiou-Diamandis A, Clark GM, Diamandis EP. IGF-I, IGF-II, IGFBP-1, and IGFBP-3 as prognostic markers of breast cancer. *Proceedings of the 10th International Congress of Endocrinology* 2:756; 1996.
25. **Yu H**, Levesque MA, Clark GM, Diamandis EP. Prognostic value of PSA in breast cancer - a large U.S. cohort study. *AACR Proceedings* 38:437; 1997.
26. Levesque MA, **Yu H**, Clark GM, Diamandis EP. p53 protein accumulation detected by an ELISA technique is a prognostic factor in a large cohort of breast cancer patients. *AACR Proceedings* 38:255; 1997.
27. Castracane VD, Gimpel T, Street L, Tawwater B, Savjani G, Micar M, **Yu H**. Osteocalcin and crosslaps: a large clinical cross sectional study of bone markers in women with and without estrogen replacement therapy. *The 79th Annual Meeting of the endocrine society, Program and Abstracts* P3-230; 1997.
28. Castracane VD, **Yu H**, Nicar M, Morrison A, Street L, Tawwater B, Gimpel TL, Dimarino P, Savjani G. Increase in the ratio of bone formation to bone resorption marker levels may indicate impairment of bone formation in postmenopausal women. *The 19th Annual Meeting of the American Society for Bone and Mineral Research* S591; 1997.
29. **Yu H**, Levesque MA, Khosravi MJ, Diamandis EP, Clark GM. Insulin-like growth factor binding protein-3 and breast cancer recurrence. *AACR Proceeding* 39:232; 1998.

30. **Yu H**, Spitz M, Mistry J, Gu J, Hong WK, Wu X. A case-control study of lung cancer in relation to insulin-like growth factors I and II and insulin-like growth factor binding protein 3. AACR Proceeding 39:629; 1998.
31. **Yu H**, Khosravi M, Diamandi A, Mistry J, Nicar M, Savjani G. Levels of IGF-I and IGF-II are higher in serum than plasma. AACC annual meeting, 1998.
32. **Yu H**, Mistry J, Nicar M, Rao J, Savjani G, Khosravi M, Diamandi A. Levels of IGFBP-2, -3, -6 and ALS in serum are different from those in plasma. AACC annual meeting, 1998.
33. Klijn JGM, Diamandis EP, **Yu H**, Look MP, Meijer-van Golder ME, van Putten WLJ, Foekens JA. Expression of prostate specific antigen correlates with poor response to tamoxifen therapy in recurrent breast cancer. AACR Proceeding 39:553; 1998.
34. Levesque MA, Lianidou ES, Angelopoulou K, **Yu H**, Genta F, Durando A, Massobrio M, Bharaj B, Diamandis EP, Katsaros D. Mutational analysis versus ELISA for the detection of p53 gene abnormalities in ovarian carcinoma. AACR Proceeding 39:230; 1998.
35. Katsaros D, Levesque M, Genta F, Durando A, Arisio R, **Yu H**, Diamandis EP, Massobrio M. Prognostic and predictive implications of p53 and WAF1 expression in ovarian cancer. AACR Proceeding 39:231; 1998.
36. Angelopoulou K, **Yu H**, Diamandis EP. Mutational spectrum of the p53 gene, tumor p53 protein overexpression and serum p53 autoantibody generation in patients with breast cancer. AACR Proceeding 39:547; 1998.
37. Black MH, Giai M, **Yu H**, Diamandis EP. Serum prostate specific antigen levels are elevated in females with breast cancer. AACR Proceeding 39:553; 1998.
38. Melegos DN, Diamandis EP, Helle SI, **Yu H**, Lundgren S, Lonning PE. Plasma prostate specific antigen levels and prognostic value in patients with metastatic breast cancer following megestrol acetate treatment. AACR Proceeding 39:553; 1998.
39. **Yu H**, Bharaj B, Giai M, Diamandis EP. CAG repeats of the androgen receptor gene in breast cancer and its association with survival. AACR Proceeding 40:380, 1999.
40. Wu X, Spitz MR, Hong WK, **Yu H**. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. AACR Proceeding 40:89, 1999.
41. Vassilikos EJK, **Yu H**, Trachtenberg J, Nam R, Narod S, Diamandis EP. How many prostate cancer patients are considered 'cured' after radical prostatectomy? AACR Proceeding 40:381, 1999.
42. Levesque MA, **Yu H**, Genta F, Massobrio M, Durando A, Bellino R, Diamandis EP, Katsaros D. Expression of p53 but not WAF1 is a predictor of response to platinum-based chemotherapy in patients with epithelial ovarian cancer. AACR Proceeding 40:382, 1999.
43. **Yu H**, Shu XO, Li BDL, Dia Q, Berkel H, Ji F, Zheng W. High plasma insulin-like growth factors (IGFs) and IGF binding protein-3 (IGFBP-3) are associated with breast cancer risk in Chinese Women. American Society of Preventive Oncology, 2000.
44. **Yu H**, van Wert JM, Eastham J Smith M, Bashambu M, Glass J, Singal R. CpG island methylation in the promoter region of the Glutathione S-transferase p1 (GSTP1) gene in peripheral blood DNA and prostate cancer risk. American Society of Preventive Oncology, 2000.